Chicago, IL10 Active Studies

Head and Neck Cancer Clinical Trials in Chicago, IL

Find 10 actively recruiting head and neck cancer clinical trials in Chicago, IL. Connect with local research sites and explore new treatment options.

10
Active Trials
10
Sponsors
2,819
Enrolling

Recruiting Head and Neck Cancer Studies in Chicago

RecruitingChicago, ILNCT06788990

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficeraf...

650 participants
Bicara Therapeutics
View Study Details
RecruitingChicago, ILNCT05451004

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph...

510 participants
Canadian Cancer Trials Group
View Study Details
RecruitingChicago, ILNCT06064877

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and ...

410 participants
AVEO Pharmaceuticals, Inc.
View Study Details
RecruitingChicago, ILNCT06062420

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) p...

360 participants
GlaxoSmithKline
View Study Details
RecruitingChicago, ILNCT05721755

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

This phase III trial compares pembrolizumab with radiation therapy to pembrolizumab without radiation therapy (standard therapy) given after pembrolizumab plus chemotherapy for the treatment of patien...

290 participants
ECOG-ACRIN Cancer Research Group
View Study Details
RecruitingChicago, ILNCT06385080

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in...

247 participants
Janssen Research & Development, LLC
View Study Details
RecruitingChicago, ILNCT05966194

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

The purpose of this study is to determine if RRx-001, which is added on to the cisplatin and radiation treatment, reduces the incidence of severe oral mucositis in patients with head and neck cancers....

216 participants
EpicentRx, Inc.
View Study Details
RecruitingChicago, ILNCT05814666

Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

Open-label, Phase II, randomized, controlled study evaluating the efficacy and safety of danvatirsen in combination with pembrolizumab compared with pembrolizumab alone as first-line treatment of pati...

81 participants
Flamingo Therapeutics NV
View Study Details
RecruitingChicago, ILNCT05893888

Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma

Arm 1 ( Phase 2/3 Run in ): PRV111: Topical Locoregional Delivery Placed Over the Tumor Region Primary Endpoint: Overall Response Rate (ORR) Primary Objective: Demonstrate the safety and efficacy of ...

40 participants
Privo Technologies
View Study Details
RecruitingChicago, ILNCT05977907

Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).

This research is being done to see if it is safe to give investigational combination of study drugs (Pembrolizumab and IO102-103) before surgery to people with surgically resectable (removable) newly ...

15 participants
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
View Study Details

About Head and Neck Cancer Clinical Trials in Chicago

Head and neck cancers develop in the mouth, throat, larynx, sinuses, or salivary glands. HPV-related oropharyngeal cancers have been increasing in prevalence. Treatment includes surgery, radiation, chemotherapy, and immunotherapy.

There are currently 10 head and neck cancer clinical trials recruiting participants in Chicago, IL. These studies are seeking a combined 2,819 participants. Research is being sponsored by Bicara Therapeutics, Canadian Cancer Trials Group, AVEO Pharmaceuticals, Inc. and 7 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Head and Neck Cancer Clinical Trials in Chicago — FAQ

Are there head and neck cancer clinical trials in Chicago?

Yes, there are 10 head and neck cancer clinical trials currently recruiting in Chicago, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Chicago?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chicago research site will contact you about next steps.

Are clinical trials in Chicago free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chicago studies also compensate for your time and travel.

What head and neck cancer treatments are being tested?

The 10 active trials in Chicago are testing new therapies including novel drugs, biologics, and treatment approaches for head and neck cancer.

Data updated March 2, 2026 from ClinicalTrials.gov